Description of Medical ServiceThis application seeks to extend availability of a test already funded on the MBS for use of gefitinib for first-line treatment in patients with locally advanced or metastatic NSCLC.
Description of Medical ConditionThere are three histological defined subgroups of NSCLC: (i) adenocarcinoma – often found in an outer area of the lung; (ii) squamous cell carcinoma – usually found in the centre of the lung by an air tube (bronchus); and (iii) large cell carcinoma – may occur in any part of the lung which tends to grow and spread faster than the other two types.
Regardless of the subgroup, NSCLC arises as a consequence of either acquired (somatic) and/or inherited (germ-line) mutations.
Reason for Application-
Medical Service Type-
Previous Application NumberNot Applicable
PICO ConfirmationFinal Decision Analytic Protocol (DAP) (PDF 394 KB)
Final Decision Analytic Protocol (DAP) (Word 747 KB)
Public Summary DocumentPublic Summary Document - November 2012 (PDF 927 KB)
Public Summary Document - November 2012 (Word 329 KB)
Public Summary Document - August 2013 (PDF 129 KB)
Public Summary Document - August 2013 (Word 99 KB)
Predicted versus ActualPublic Summary Document - November 2016 (Word 153 KB)
Public Summary Document - November 2016 (PDF 823 KB)
Meetings for this Application
PASC7 July 2011
14 - 15 September 2011
ESC11 - 12 October 2012
MSAC29 - 30 November 2012
1 August 2013
24-25 November 2016